Skip to main content

Table 3 Percentage of CD4+25+ T cell Subset

From: Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

Pt. # Pre(0w) Post(8w)
R-M-1 12.47% 1.70%
R-G-2 10.00% 1.59%
R-K-3 1.02% 1.88%
R-H-4 4.40% 5.83%
R-N-5 4.74% 6.20%
R-L-6 2.70% 3.59%
B-S-1 3.31% 5.94%
B-H-2 4.54% 9.29%
B-L-3 3.66% 7.05%
B-Y-4 8.18% 6.08%